Risk of culture-confirmed borrelial persistence in patients treated for erythema migrans and possible mechanisms of resistance

International Journal of Medical Microbiology : IJMM
Klaus-Peter HunfeldF Strle

Abstract

Erythema migrans (EM) develops at the site of the tick bite in 77-90% of Lyme borreliosis (LB) patients and is therefore a common manifestation of early disease. Clinical treatment failures have been reported in early LB cases for almost every suitable antimicrobial agent. The exact risk of resistance to antibiotic treatment in patients with EM, however, is not known and there are few published cases of culture-proven treatment failure. Moreover, currently available diagnostic techniques cannot reliably discriminate between possible reinfection, true endogenous relapse and co-infection with other tick-borne pathogens. These drawbacks together with the phenomenon of resistance to therapy in individual patients undoubtedly contribute to the inconsistencies surrounding the optimal treatment regimens for LB and are often misinterpreted and misused to support prolonged antibiotic treatment regimens. The question for the underlying mechanisms of possible antimicrobial resistance in Borrelia burgdorferi sensu lato remains unresolved but a better understanding of such genetic or phenotypic mechanisms would be helpful for the treatment of LB and other spirochetal diseases. Investigations on this issue, at best, should start with borreli...Continue Reading

References

Feb 1, 1991·The Journal of Infectious Diseases·H W PfisterK M Einhäupl
Dec 1, 1986·Zentralblatt Für Bakteriologie, Mikrobiologie, Und Hygiene. Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology·V Preac-MursicG Schierz
Oct 1, 1993·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A P van DamJ Dankert
Jul 1, 1996·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·F StrleR N Picken
Jan 1, 1997·Journal of Clinical Microbiology·R K StraubingerM J Appel
Dec 1, 1996·The American Journal of Dermatopathology·E AbererW Jurecka
Apr 15, 2000·Annals of Internal Medicine·W T Thanassi, R T Schoen
Jun 22, 2000·Archives of Family Medicine·J NowakowskiG P Wormser
Aug 15, 2001·Antimicrobial Agents and Chemotherapy·P KraiczyK P Hunfeld
Feb 1, 1997·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Sjoerd G. T. RijpkemaJoop F.P. Schellekens
Oct 18, 2002·Antimicrobial Agents and Chemotherapy·Darya TerekhovaFelipe C Cabello
Oct 31, 2002·The Journal of Infectious Diseases·Linda K BockenstedtDurland Fish
Apr 4, 2003·International Journal of Antimicrobial Agents·Klaus-Peter HunfeldThomas A Wichelhaus
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·Klaus-Peter HunfeldPeter Kraiczy
May 6, 2005·International Journal of Antimicrobial Agents·Eva Ruzić-SabljićFranc Strle

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.